The Emirate of Abu Dhabi has announced an advanced step in the field of delicate medicine by inserting the “APOE E4” test within the reports of the genetic pharmacy of Al -Zheimer’s patients, as part of efforts to develop customized treatment plans based on the genetic composition of patients, which enhances the efficiency and safety of health care provided. This achievement comes as a fruit of cooperation between the Department of Health in Abu Dhabi and the M42 “The APOE E4” test allows the identification of patients most vulnerable to dangerous side effects such as swelling or brain bleeding when they receive treatments based on antibodies to anti -amyloid antibodies, which enables doctors to design more accurate and effective treatment plans. The doctor confirmed
source
